“There remains a high unmet medical need for patients with MDS or beta-thalassemia who suffer from the effects of their disease-related anemia,” said Jay Backstrom, Celgene’s chief medical ...

Jay Backstrom, chief medical officer for Celgene, said: “New oral treatment options with differentiated profiles like ozanimod are needed to help address an unmet need for people with relapsing ...